PD-1抑制剂免疫相关不良反应的研究进展
| 作者: |
1,2唐淑慧,
3李丽,
3侯黎莉
1 同济大学医学院，上海 200092 2 上海长海医院肿瘤科，上海 200433 3 上海市第九人民医院护理部，上海 200011 |
| 通讯: |
侯黎莉
Email: pisces_liz@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2021.03.036 |
| 基金: | 上海长海医院护理立项课题(2018HLZD03)。 |
摘要
免疫检查点抑制剂(immune checkpoint inhibitors，ICI)的应用是肿瘤治疗领域的重大突破，是恶性肿瘤患者新的选择和希望。国家食品与药品管理监督局(Chinese Food and Drug Administration，CFDA)批准程序性细胞死亡蛋白-1(programmed cell death protein 1，PD-1)免疫抑制剂用于多种肿瘤的治疗。但是PD-1抑制剂可引起自身免疫毒性，虽然大多数免疫相关不良反应(immune-related adverse events，irAEs)以1~2级为主，但仍有部分患者发生危及生命的3~4级免疫毒性反应。
关键词：
程序性细胞死亡蛋白-1；免疫检查点抑制剂；免疫治疗；免疫相关不良反应
Research progress of immune-related adverse reactions of PD-1 inhibitors
CorrespondingAuthor: HOU Lili Email: pisces_liz@163.com
DOI: 10.3978/j.issn.2095-6959.2021.03.036
Foundation: This work was supported by the Shanghai Changhai Hospital Nursing Project, China (2018HLZD03).
Abstract
The application of immune checkpoint inhibitors (ICI) is a major breakthrough in the field of tumor treatment, and it is a new choice and hope for patients with malignant tumors. Chinese Food and Drug Administration (CFDA) has approved programmed cell death protein 1 (PD-1) inhibitors for the treatment of a a variety of tumors. However, PD-1 inhibitors can cause autoimmune toxicity. Although most immune-related adverse events (irAEs) are in the level of grade 1–2, some patients still have life-threatening immunotoxic response in the level of grade 3–4.
Keywords：
programmed cell death protein 1; immune checkpoint inhibitor; immunotherapy; immune-related adverse reactions; nursing management